Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier

X
Drug Profile

Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier

Alternative Names: Macromolecular micelle paclitaxel; NK 105; Polymeric micelle paclitaxel

Latest Information Update: 26 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoCarrier
  • Developer Nippon Kayaku
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Gastric cancer
  • No development reported Solid tumours

Most Recent Events

  • 26 Apr 2022 Paclitaxel micelle formulation is still in phase II trials for Breast cancer (Recurrent, Late-stage disease) in Japan (IV) (JapicCTI-183868)
  • 12 Nov 2021 Nippon Kayaku completes a phase II clinical trial in Breast cancer (Recurrent, Late-stage disease) in Japan (IV) (JapicCTI-183868)
  • 09 Oct 2019 Nippon Kayaku completes enrolment in a phase II clinical trials in Breast cancer (Recurrent, Late-stage disease) in Japan before October 2019 (IV) (JapicCTI-183868)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top